HSP90 Promotes Radioresistance of Cervical Cancer Cells Via Reducing FBXO6-mediated CD147 Polyubiquitination

Overview

Journal Cancer Sci

Specialty Oncology

Date 2022 Jan 19

PMID 35043518

Authors

Qi Song

Juyi Wen

Weiping Li

Janxin Xue

Yufei Zhang

Hongyan Liu

Jixia Han

Tao Ning

Zejun Lu

Affiliations

Soon will be listed here.

Abstract

HSP90 inhibition might be a promising strategy to overcome the radioresistance of some cancers. In the current study, we further explored the mechanisms of HSP90 in regulating the radiosensitivity of cervical cancer cells. Bioinformatic analysis was performed based on data from TCGA-CESC. Cellular and molecular studies were conducted using CaSki and SiHa and the derived radioresistant (RR) subclones. Through a proteomics screen, we identified HSP90 chaperones (both HSP90α and HSP90β) as CD147-binding partners supporting its stabilization. Targeting HSP90 sensitized CaSki-RR and SiHa-RR cancer cells to irradiation partially through CD147 destabilization. Mechanistically, HSP90 interacts with FBXO6 and reduces FBXO6-mediated proteasomal degradation of CD147. Enforced FBXO6 overexpression also sensitized CaSki-RR and SiHa-RR cancer cells to irradiation. These effects were enhanced using 17-AAG treatment but were weakened by CD147 overexpression. Survival analysis further confirmed the association between high FBXO6 expression and favorable progression-free survival among patients with cervical cancer. In conclusion, this study showed that HSP90 promotes radioresistance of cervical cancer cells partially via reducing FBXO6 mediated CD147 polyubiquitination. These findings help to explain why HSP90 inhibitor exerts radio-sensitizing effects in cervical cancer.

Citing Articles

Carboplatin-resistance-related DNA damage repair prognostic gene signature and its association with immune infiltration in breast cancer.

Dong S, Li A, Pan R, Hong J, Wang Z, Shen K Front Immunol. 2025; 16:1522149.

PMID: 39944694 PMC: 11813922. DOI: 10.3389/fimmu.2025.1522149.

AdipoR1 enhances the radiation resistance via ESR1/CCNB1IP1/cyclin B1 pathway in hepatocellular carcinoma cells.

Gan Y, Zhu L, Li Y, Ge R, Tian J, Chen Y Mol Med. 2025; 31(1):21.

PMID: 39849382 PMC: 11755959. DOI: 10.1186/s10020-025-01065-0.

Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck Cancer.

de Bakker T, Maes A, Dragan T, Martinive P, Penninckx S, Van Gestel D Cells. 2025; 14(1.

PMID: 39791719 PMC: 11719474. DOI: 10.3390/cells14010018.

Functional and therapeutic significant of heat-shock protein 90 (HSP90) in reproductive cancers.

He B, Wang L Clin Transl Oncol. 2024; .

PMID: 39369360 DOI: 10.1007/s12094-024-03743-7.

Global profiling of transcriptome, proteome and 2-hydroxyisobutyrylome in radioresistant lung adenocarcinoma cell.

Lei Z, He J, Yang H, Zhang L, Lai T, Zhou L BMC Genomics. 2024; 25(1):923.

PMID: 39363283 PMC: 11448304. DOI: 10.1186/s12864-024-10854-6.

References

Kim K, Lee S, Hwang H, Lee J, Ji E, An H . Direct Monitoring of Fucosylated Glycopeptides of Alpha-Fetoprotein in Human Serum for Early Hepatocellular Carcinoma by Liquid Chromatography-Tandem Mass Spectrometry with Immunoprecipitation. Proteomics Clin Appl. 2018; 12(6):e1800062. DOI: 10.1002/prca.201800062. View

Bodgi L, Foray N . The nucleo-shuttling of the ATM protein as a basis for a novel theory of radiation response: resolution of the linear-quadratic model. Int J Radiat Biol. 2016; 92(3):117-31. DOI: 10.3109/09553002.2016.1135260. View

Eichner R, Heider M, Fernandez-Saiz V, van Bebber F, Garz A, Lemeer S . Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med. 2016; 22(7):735-43. DOI: 10.1038/nm.4128. View

Song Q, Wen J, Li W, Xue J, Zhang Y, Liu H . HSP90 promotes radioresistance of cervical cancer cells via reducing FBXO6-mediated CD147 polyubiquitination. Cancer Sci. 2022; 113(4):1463-1474. PMC: 8990293. DOI: 10.1111/cas.15269. View

Ji M, Zhao Z, Li Y, Xu P, Shi J, Li Z . FBXO6-mediated RNASET2 ubiquitination and degradation governs the development of ovarian cancer. Cell Death Dis. 2021; 12(4):317. PMC: 7994844. DOI: 10.1038/s41419-021-03580-4. View

Zhang X, Komaki R, Wang L, Fang B, Chang J . Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res. 2008; 14(9):2813-23. PMC: 2387204. DOI: 10.1158/1078-0432.CCR-07-1528. View

Du X, Meng F, Peng D, Wang Z, Ouyang W, Han Y . Noncanonical Role of FBXO6 in Regulating Antiviral Immunity. J Immunol. 2019; 203(4):1012-1020. DOI: 10.4049/jimmunol.1801557. View

Ernst A, Anders H, Kapfhammer H, Orth M, Hennel R, Seidl K . HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. Cancer Lett. 2015; 365(2):211-22. DOI: 10.1016/j.canlet.2015.05.024. View

Chino J, Annunziata C, Beriwal S, Bradfield L, Erickson B, Fields E . Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2020; 10(4):220-234. PMC: 8802172. DOI: 10.1016/j.prro.2020.04.002. View

10.

IJff M, van Oorschot B, Oei A, Krawczyk P, Rodermond H, Stalpers L . Enhancement of Radiation Effectiveness in Cervical Cancer Cells by Combining Ionizing Radiation with Hyperthermia and Molecular Targeting Agents. Int J Mol Sci. 2018; 19(8). PMC: 6121622. DOI: 10.3390/ijms19082420. View

11.

Lauber K, Brix N, Ernst A, Hennel R, Krombach J, Anders H . Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity. Cancer Lett. 2015; 368(2):209-29. DOI: 10.1016/j.canlet.2015.02.047. View

12.

Ju X, Liang S, Zhu J, Ke G, Wen H, Wu X . Extracellular matrix metalloproteinase inducer (CD147/BSG/EMMPRIN)-induced radioresistance in cervical cancer by regulating the percentage of the cells in the G2/m phase of the cell cycle and the repair of DNA Double-strand Breaks (DSBs). Am J Transl Res. 2016; 8(6):2498-511. PMC: 4931146. View

13.

Liu B, Zheng Y, Wang T, Xu H, Xia L, Zhang J . Proteomic identification of common SCF ubiquitin ligase FBXO6-interacting glycoproteins in three kinds of cells. J Proteome Res. 2012; 11(3):1773-81. DOI: 10.1021/pr2010204. View

14.

Lee Y, Cho Y, Shin S, Choi C, Ryu J, Jeon H . Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer. Sci Rep. 2019; 9(1):15394. PMC: 6817901. DOI: 10.1038/s41598-019-51959-3. View

15.

Kim W, Oh S, Woo J, Hong W, Lee H . Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res. 2009; 69(4):1624-32. PMC: 2646382. DOI: 10.1158/0008-5472.CAN-08-0505. View

16.

Wu Y, Zhou X, Zheng P . Involvement of CD147 isoform‑4 in the proliferation of SiHa cells: a possible molecular mechanism of cervical cancer. Oncol Rep. 2011; 26(3):717-24. DOI: 10.3892/or.2011.1345. View

17.

Yang H, Chen B . CD147 in ovarian and other cancers. Int J Gynecol Cancer. 2012; 23(1):2-8. DOI: 10.1097/IGC.0b013e3182749139. View

18.

Nagaraju G, Zakka K, Landry J, Shaib W, Lesinski G, El-Rayes B . Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Int J Cancer. 2019; 145(6):1529-1537. DOI: 10.1002/ijc.32227. View

19.

Biau J, Chautard E, Verrelle P, Dutreix M . Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting. Front Oncol. 2019; 9:1009. PMC: 6795692. DOI: 10.3389/fonc.2019.01009. View

20.

He S, Smith D, Sequeira M, Sang J, Bates R, Proia D . The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs. 2014; 32(4):577-86. PMC: 4101249. DOI: 10.1007/s10637-014-0095-4. View